Of note, subset analysis suggested that PFS improvement with olaparib appeared greater in the TNBC subgroup (HR, 0.43; 95% CI, 0.29–0.63) than in the hormone receptor–positive subgroup (HR, 0.82; 95% CI, 0.55–1.26).
Evidence (talazoparib): TheEMBRACAtrial (NCT01945775) was a randomized, open label, phase III trial that assigned 431 patients with germlineBRCA1orBRCA2pathogenic variants and locally advanced or metastatic breast cancer in a 2:1 ratio to talazoparib (1 mg PO qd) or standard single-agent chemotherapy of the physician’s choice (eribulin, capecitabine, gemcitabine, or vinorelbine).[87] All patients had received previous treatment with an anthracycline, taxane, or both.